Overview

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Status:
Withdrawn

Trial end date:
2018-02-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and efficacy of intratumoral REOLYSIN® therapy alone and in combination with standard neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Oncolytics Biotech

Treatments:

Cisplatin
Gemcitabine